Aptevo Therapeutics Inc. — FY 2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This is an annual report, not a quarterly report. Aptevo is a clinical-stage biotechnology company developing cancer immunotherapies using its ADAPTIR and ADAPTIR-FLEX platforms. It had no product candidates approved for commercial distribution; reported royalty revenue was primarily tied to Pfizer’s RUXIENCE sales. The former IXINITY business was sold to Medexus in 2020 and is reported as discontinued operations.
Financial performance and liquidity
| Metric | FY 2021 | FY 2020 |
|---|---|---|
| Royalty revenue | $12.3 million | $4.3 million |
| Research and development | $19.0 million | $17.9 million |
| General and administrative | $14.7 million | $14.0 million |
| Loss from operations | $21.4 million | $27.5 million |
| Net loss | $28.5 million | $17.8 million |
| Net cash used in operating activities | $21.7 million | $29.3 million |
- Royalty revenue increased $8.0 million year over year. Operating expenses also rose modestly; the wider net loss primarily reflected higher other expense, including interest and non-cash interest associated with the royalty financing.
- FY 2020 net income from discontinued operations was $13.2 million, including a $14.3 million gain on the IXINITY business sale. FY 2021 discontinued-operations income was $1.0 million. This makes reported net loss comparisons less indicative of continuing operations: continuing-operations net loss was $29.4 million in 2021 versus $30.9 million in 2020.
- At year-end, cash and cash equivalents were $45.0 million, restricted cash was $1.3 million, and current assets were $52.6 million. Total liabilities were $55.4 million and stockholders’ equity was $1.2 million.
- Cash flows were $(21.7) million from operations, $(0.7) million from investing, and $26.2 million from financing. Financing included $35.0 million from the sale of future RUXIENCE royalties and $10.2 million from Lincoln Park share sales, offset in part by debt and royalty-liability payments.
- MidCap term-loan principal was $15.0 million at year-end. Separately, the HCR liability for sold future royalties was $31.0 million, including $15.5 million classified as current. The filing reports $16.0 million of scheduled principal and interest payments on the MidCap loan.
Business developments, outlook, and risks
- APVO436: The company completed Phase 1b dose escalation and began a multi-center expansion study planned for up to 90 adults with AML across five cohorts, testing monotherapy and combinations. In the dose-escalation trial, 46 AML and MDS patients were enrolled; 11 of 40 evaluable patients had a reported favorable response, including two AML complete remissions and three MDS marrow complete responses. These are early-stage, limited-patient results and do not establish efficacy in later trials.
- APVO436-related adverse events included infusion-related reactions in 13 of 46 patients (28.3%) and cytokine release syndrome in 10 of 46 (21.7%). The filing says CRS was generally manageable with standard treatment; serious or unexpected safety findings remain a development risk.
- ALG.APV-527: Aptevo and Alligator planned to submit an IND in the second half of 2022 and expected a first-in-human study in that period. These are forward-looking expectations, not completed milestones.
- Other candidates: APVO603 and APVO442 remained preclinical. The company highlighted continued development of its platforms and potential collaborations but gave no quantified revenue, earnings, or cash-flow guidance.
- Aptevo received $35 million from HCR in March 2021 in exchange for RUXIENCE royalty rights, with eligibility for up to $32.5 million in sales milestone payments. A $10 million milestone was received in March 2022; up to $22.5 million in additional milestone payments remained possible for 2023 and 2024. The agreement is accounted for as a debt-like liability, and future amounts depend on RUXIENCE sales.
- Management said existing resources and expected funding sources were sufficient for at least twelve months from filing, while also stating that substantial additional funds would be needed to advance development and that capital might not be available on acceptable terms. The company continued to incur losses and had an accumulated deficit of $214.1 million.
- Key risks include clinical-trial failure or delay, patient enrollment and COVID-19-related disruption, safety events, reliance on third-party manufacturers and trial operators, dependence on Pfizer and Medexus for sales-linked proceeds, debt covenants and repayment needs, and potential dilution from future equity issuance. The company also cited inflation, supply constraints, stockholder activism, and competition.
- The independent auditor issued an unqualified opinion on the financial statements and identified the HCR royalty-liability and non-cash interest estimate as a critical audit matter. Management concluded disclosure controls and internal control over financial reporting were effective as of year-end; the auditor did not provide an internal-control attestation.
Most important facts for investors to verify
- Whether APVO436 expansion-trial enrollment, safety, and response data support advancement beyond early-stage testing.
- Whether ALG.APV-527 reached IND submission and first-in-human study milestones on the stated timetable.
- Actual RUXIENCE sales and HCR milestone payments, and how the royalty liability and related non-cash interest change as forecasts are updated.
- Cash burn, required financing, MidCap debt repayment progress, and dilution from Lincoln Park or other equity financing.
- Whether Medexus generates further IXINITY-related deferred payments and whether clinical, manufacturing, or pandemic-related disruptions affect operations.